Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030, the company states.

“With this first approval of Datroway in the US, we continue to deliver on our ambition for antibody drug conjugates to improve upon and replace conventional chemotherapy for the treatment of multiple cancers. We are proud to bring Datroway to people living with metastatic HR-positive, HER2-negative breast cancer, and this approval marks the eighth new medicine of the 20 we have set out to deliver across AstraZeneca by 2030,” says Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca.

Related article

Exclusive R&D interview: David Fredrickson

In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug development within oncology and how we can create faster access to innovative medicines. “Drug development within oncology has evolved to become more flexible,” said David Fredrickson, head of AstraZeneca’s oncology business unit. “Clinical trials with […]


Antibody drug conjugate

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The approval by the US Food and Drug Administration (FDA) was based on results from the TROPION-Breast01 Phase III trial.

Datroway is a specifically engineered TROP2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Additional regulatory submissions for Datroway in breast cancer are under review in the EU, China and other regions.